Global Dermatophytic Onychomycosis Treatment Industry

Global Dermatophytic Onychomycosis Treatment Market to Reach $6. 5 Billion by 2027. Amid the COVID-19 crisis, the global market for Dermatophytic Onychomycosis Treatment estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$6.

New York, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Dermatophytic Onychomycosis Treatment Industry" - https://www.reportlinker.com/p05956564/?utm_source=GNW
5 Billion by 2027, growing at a CAGR of 11.8% over the analysis period 2020-2027. Systemic Therapy, one of the segments analyzed in the report, is projected to record a 10.7% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Topical Therapy segment is readjusted to a revised 12.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $874.9 Million, While China is Forecast to Grow at 11.4% CAGR

The Dermatophytic Onychomycosis Treatment market in the U.S. is estimated at US$874.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 11.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.3% and 10.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.7% CAGR.

Device-based Therapy Segment to Record 11.2% CAGR

In the global Device-based Therapy segment, USA, Canada, Japan, China and Europe will drive the 11% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.8 Million in the year 2020 will reach a projected size of US$186.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$771 Million by the year 2027.We bring years of research experience to this 9th edition of our report. The 182-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

• Allergan PLC

• Galderma SA

• GlaxoSmithKline PLC

• Johnson & Johnson

• Moberg Pharma AB

• NovaBiotics Ltd

• Novartis AG

• Pfizer, Inc.

• Sanofi SA

• Valeant Pharmaceuticals International, Inc.

Read the full report: https://www.reportlinker.com/p05956564/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Dermatophytic Onychomycosis Treatment Competitor Market Share
Scenario Worldwide (in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 2: World Historic Review for Dermatophytic Onychomycosis
Treatment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019

Table 3: World 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2012, 2020 &
2027

Table 4: World Current & Future Analysis for Systemic Therapy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 5: World Historic Review for Systemic Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 6: World 15-Year Perspective for Systemic Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Topical Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 8: World Historic Review for Topical Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 9: World 15-Year Perspective for Topical Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Device-based
Therapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 11: World Historic Review for Device-based Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 12: World 15-Year Perspective for Device-based Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 14: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 15: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 16: World Current & Future Analysis for Dermatology
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 17: World Historic Review for Dermatology Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 18: World 15-Year Perspective for Dermatology Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Retail Pharmacies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 20: World Historic Review for Retail Pharmacies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 21: World 15-Year Perspective for Retail Pharmacies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 23: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 24: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Dermatophytic Onychomycosis Treatment Market Share (in %) by
Company: 2019 & 2025
Market Analytics
Table 25: USA Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 26: USA Historic Review for Dermatophytic Onychomycosis
Treatment by Segment - Systemic Therapy, Topical Therapy and
Device-based Therapy Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 27: USA 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 28: USA Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 29: USA Historic Review for Dermatophytic Onychomycosis
Treatment by End-Use - Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 30: USA 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

CANADA
Table 31: Canada Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 32: Canada Historic Review for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 33: Canada 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 34: Canada Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 35: Canada Historic Review for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 36: Canada 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

JAPAN
Table 37: Japan Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 38: Japan Historic Review for Dermatophytic Onychomycosis
Treatment by Segment - Systemic Therapy, Topical Therapy and
Device-based Therapy Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 39: Japan 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 40: Japan Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 41: Japan Historic Review for Dermatophytic Onychomycosis
Treatment by End-Use - Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 42: Japan 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

CHINA
Table 43: China Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 44: China Historic Review for Dermatophytic Onychomycosis
Treatment by Segment - Systemic Therapy, Topical Therapy and
Device-based Therapy Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 45: China 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 46: China Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 47: China Historic Review for Dermatophytic Onychomycosis
Treatment by End-Use - Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 48: China 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

EUROPE
Market Facts & Figures
European Dermatophytic Onychomycosis Treatment Market:
Competitor Market Share Scenario (in %) for 2019 & 2025
Market Analytics
Table 49: Europe Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027

Table 50: Europe Historic Review for Dermatophytic
Onychomycosis Treatment by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 51: Europe 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 53: Europe Historic Review for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 54: Europe 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 56: Europe Historic Review for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 57: Europe 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

FRANCE
Table 58: France Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 59: France Historic Review for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 60: France 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 61: France Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 62: France Historic Review for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 63: France 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

GERMANY
Table 64: Germany Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 65: Germany Historic Review for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 66: Germany 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 67: Germany Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 68: Germany Historic Review for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 69: Germany 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

ITALY
Table 70: Italy Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 71: Italy Historic Review for Dermatophytic Onychomycosis
Treatment by Segment - Systemic Therapy, Topical Therapy and
Device-based Therapy Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 72: Italy 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 73: Italy Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 74: Italy Historic Review for Dermatophytic Onychomycosis
Treatment by End-Use - Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 75: Italy 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 76: UK Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 77: UK Historic Review for Dermatophytic Onychomycosis
Treatment by Segment - Systemic Therapy, Topical Therapy and
Device-based Therapy Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 78: UK 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 79: UK Current & Future Analysis for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 80: UK Historic Review for Dermatophytic Onychomycosis
Treatment by End-Use - Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 81: UK 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 82: Rest of Europe Current & Future Analysis for
Dermatophytic Onychomycosis Treatment by Segment - Systemic
Therapy, Topical Therapy and Device-based Therapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 83: Rest of Europe Historic Review for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 84: Rest of Europe 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 85: Rest of Europe Current & Future Analysis for
Dermatophytic Onychomycosis Treatment by End-Use - Hospitals,
Dermatology Clinics, Retail Pharmacies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027

Table 86: Rest of Europe Historic Review for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 87: Rest of Europe 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 88: Asia-Pacific Current & Future Analysis for
Dermatophytic Onychomycosis Treatment by Segment - Systemic
Therapy, Topical Therapy and Device-based Therapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 89: Asia-Pacific Historic Review for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 90: Asia-Pacific 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 91: Asia-Pacific Current & Future Analysis for
Dermatophytic Onychomycosis Treatment by End-Use - Hospitals,
Dermatology Clinics, Retail Pharmacies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027

Table 92: Asia-Pacific Historic Review for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 93: Asia-Pacific 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

REST OF WORLD
Table 94: Rest of World Current & Future Analysis for
Dermatophytic Onychomycosis Treatment by Segment - Systemic
Therapy, Topical Therapy and Device-based Therapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027

Table 95: Rest of World Historic Review for Dermatophytic
Onychomycosis Treatment by Segment - Systemic Therapy, Topical
Therapy and Device-based Therapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 96: Rest of World 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by Segment - Percentage Breakdown of
Value Sales for Systemic Therapy, Topical Therapy and
Device-based Therapy for the Years 2012, 2020 & 2027

Table 97: Rest of World Current & Future Analysis for
Dermatophytic Onychomycosis Treatment by End-Use - Hospitals,
Dermatology Clinics, Retail Pharmacies and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027

Table 98: Rest of World Historic Review for Dermatophytic
Onychomycosis Treatment by End-Use - Hospitals, Dermatology
Clinics, Retail Pharmacies and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 99: Rest of World 15-Year Perspective for Dermatophytic
Onychomycosis Treatment by End-Use - Percentage Breakdown of
Value Sales for Hospitals, Dermatology Clinics, Retail
Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 44
Read the full report: https://www.reportlinker.com/p05956564/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001